◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Fennec Pharmaceuticals Inc.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024
Total Revenue 12.5M 9.7M 8.8M 7.9M 7.0M
Operating Revenue 13.7M 10.9M 10.8M 2.6M 8.0M
Cost Of Revenue 660,000 967,000 373,000 669,000 1.4M
Gross Profit 11.8M 8.7M 8.4M 7.3M 5.6M
Selling General And Administration 12.0M 11.3M 9.1M 8.1M 10.7M
General And Administrative Expense 6.8M 7.0M 6.1M 4.2M 6.1M
Research And Development 29,000 107,000 94,000 50,000 97,000
Depreciation And Amortization In Income Statement 12,000 -- 13,000 25,000 21,000
Operating Expense 12.0M 11.4M 9.2M 8.2M 10.8M
Operating Income -201,000 -2.7M -821,000 -959,000 -5.2M
EBIT -52,000 -2.6M -573,000 -654,000 -4.7M
Interest Expense 586,000 594,000 592,000 966,000 1.0M
Interest Expense Non Operating 586,000 594,000 592,000 966,000 1.0M
Interest Income 152,000 171,000 236,000 399,000 516,000
Interest Income Non Operating 152,000 171,000 236,000 399,000 516,000
Net Interest Income -434,000 -436,000 -356,000 -567,000 -509,000
Other Income Expense -3,000 16,000 12,000 -94,000 -3,000
Gain On Sale Of Security -3,000 16,000 12,000 -94,000 -3,000
Pretax Income -638,000 -3.2M -1.2M -1.6M -5.7M
Tax Effect Of Unusual Items 0.00 0.00 0.00 0.00 0.00
Net Income From Continuing And Discontinued Operation -638,000 -3.2M -1.2M -2.0M -5.7M
Net Income From Continuing Operation Net Minority Interest -638,000 -3.2M -1.2M -2.0M -5.7M
Net Income Including Noncontrolling Interests -638,000 -3.2M -1.2M -2.0M -5.7M
Net Income Common Stockholders -638,000 -3.2M -1.2M -2.0M -5.7M
Net Income -638,000 -3.2M -1.2M -2.0M -5.7M
EBITDA -26,000 -2.5M -547,000 -628,000 -4.7M
Normalized EBITDA -23,000 -2.5M -559,000 -534,000 -4.7M
Reconciled Depreciation 26,000 25,000 26,000 26,000 25,000
Basic EPS -0.02 -0.11 -0.04 -0.06 -0.21
Diluted EPS -0.02 -0.11 -0.04 -0.06 -0.21
Basic Average Shares 27.9M 27.7M 27.6M 27.5M 27.4M
Diluted Average Shares 27.9M 27.7M 27.6M 27.5M 27.4M
Total Unusual Items -3,000 16,000 12,000 -94,000 -3,000
Total Unusual Items Excluding Goodwill -3,000 16,000 12,000 -94,000 -3,000
Tax Rate For Calcs 0.00 0.00 0.00 0.00 0.00
Normalized Income -635,000 -3.2M -1.2M -1.9M -5.7M
Amortization 12,000 -- 13,000 25,000 21,000
Amortization Of Intangibles Income Statement 12,000 -- 13,000 25,000 21,000
Depreciation Amortization Depletion Income Statement 12,000 -- 13,000 25,000 21,000
Diluted NI Availto Com Stockholders -638,000 -3.2M -1.2M -2.0M -5.7M
Net Income Continuous Operations -638,000 -3.2M -1.2M -2.0M -5.7M
Net Non Operating Interest Income Expense -434,000 -436,000 -356,000 -567,000 -509,000
Other Gand A 6.8M 7.0M 6.1M 4.2M 6.1M
Reconciled Cost Of Revenue 646,000 967,000 360,000 668,000 1.4M
Selling And Marketing Expense 5.2M 4.4M 2.9M 3.9M 4.6M
Total Expenses 12.7M 12.4M 9.6M 8.9M 12.2M
Total Operating Income As Reported -189,000 -2.7M -808,000 -934,000 -5.2M
Total Other Finance Cost -- 13,000 13,000 25,000 21,000
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024
Cash And Cash Equivalents 21.9M 18.7M 22.7M 26.6M 40.3M
Cash Cash Equivalents And Short Term Investments 21.9M 18.7M 22.7M 26.6M 40.3M
Accounts Receivable 19.3M 17.5M 15.4M 12.9M 12.9M
Receivables 19.3M 17.5M 15.4M 12.9M 12.9M
Inventory 2.5M 2.2M 1.4M 1.1M 1.1M
Prepaid Assets 1.4M 1.4M 2.4M 3.1M 3.1M
Other Current Assets 898,000 965,000 1.0M 466,000 546,000
Current Assets 46.1M 40.8M 43.0M 44.1M 58.0M
Other Non Current Assets 743,000 768,000 794,000 822,000 956,000
Total Non Current Assets 3.2M 4.1M 3.4M 822,000 956,000
Total Assets 49.3M 44.9M 46.4M 44.9M 58.9M
Current Debt And Capital Lease Obligation -- -- -- 2,000 7,000
Accounts Payable 5.9M 5.9M 5.3M 3.2M 3.9M
Payables 5.9M 5.9M 5.3M 3.2M 3.9M
Payables And Accrued Expenses 9.6M 8.2M 8.1M 6.7M 7.2M
Current Accrued Expenses 3.7M 2.2M 2.8M 3.4M 3.3M
Current Deferred Revenue 248,000 248,000 248,000 248,000 248,000
Current Liabilities 9.8M 8.4M 8.4M 6.9M 7.4M
Long Term Debt 19.4M 19.4M 19.4M 19.3M 32.1M
Long Term Debt And Capital Lease Obligation 19.4M 19.4M 19.4M 19.3M 32.1M
Total Non Current Liabilities Net Minority Interest 43.9M 43.9M 43.9M 43.9M 56.7M
Total Liabilities Net Minority Interest 53.8M 52.3M 52.3M 50.8M 64.1M
Common Stock 147.7M 146.2M 146.0M 145.6M 145.4M
Capital Stock 147.7M 146.2M 146.0M 145.6M 145.4M
Additional Paid In Capital 71.2M 69.1M 67.7M 67.0M 65.8M
Retained Earnings -224.6M -224.0M -220.8M -219.7M -217.7M
Gains Losses Not Affecting Retained Earnings 1.2M 1.2M 1.2M 1.2M 1.2M
Other Equity Adjustments 1.2M 1.2M 1.2M 1.2M 1.2M
Common Stock Equity -4.5M -7.5M -5.9M -5.9M -5.2M
Stockholders Equity -4.5M -7.5M -5.9M -5.9M -5.2M
Total Equity Gross Minority Interest -4.5M -7.5M -5.9M -5.9M -5.2M
Total Capitalization 14.9M 11.9M 13.5M 13.5M 26.9M
Net Tangible Assets -4.5M -7.5M -5.9M -5.9M -5.2M
Tangible Book Value -4.5M -7.5M -5.9M -5.9M -5.2M
Working Capital 36.2M 32.4M 34.6M 37.2M 50.5M
Invested Capital 14.9M 11.9M 13.5M 13.5M 26.9M
Total Debt 19.4M 19.4M 19.4M 19.3M 32.1M
Net Debt -- 659,000 -- -- --
Share Issued 28.1M 27.7M 27.6M 27.5M 27.4M
Ordinary Shares Number 28.1M 27.7M 27.6M 27.5M 27.4M
Allowance For Doubtful Accounts Receivable -- -- -- -3.8M -5.0M
Capital Lease Obligations 0.00 0.00 0.00 2,000 7,000
Current Capital Lease Obligation 0.00 0.00 0.00 2,000 7,000
Current Deferred Liabilities 248,000 248,000 248,000 248,000 248,000
Gross Accounts Receivable -- -- -- 16.7M 17.9M
Non Current Accounts Receivable 2.5M 3.3M 2.6M -- --
Non Current Deferred Liabilities 24.6M 24.6M 24.6M 24.6M 24.6M
Non Current Deferred Revenue 24.6M 24.6M 24.6M 24.6M 24.6M
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024
Operating Cash Flow 1.5M -3.7M -4.3M -1.5M -2.2M
Cash Flow From Continuing Operating Activities 1.5M -3.7M -4.3M -1.5M -2.2M
Depreciation And Amortization 26,000 25,000 26,000 26,000 25,000
Depreciation Amortization Depletion 26,000 25,000 26,000 26,000 25,000
Stock Based Compensation 2.2M 1.5M 798,000 1.1M 1.8M
Change In Working Capital 1.5M -3.2M -4.1M 52,000 -2.8M
Changes In Account Receivables -3.4M -265,000 -5.3M -175,000 -4.2M
Change In Receivables -3.4M -265,000 -5.3M -175,000 -4.2M
Change In Inventory -276,000 -797,000 -344,000 65,000 502,000
Change In Payables And Accrued Expense 1.4M 43,000 1.5M -511,000 -305,000
Change In Payable -75,000 661,000 2.0M -626,000 -580,000
Change In Other Current Assets 520,000 102,000 -537,000 687,000 364,000
Change In Other Current Liabilities 0.00 2,000 -2,000 -- -437,000
Other Non Cash Items 14,000 13,000 13,000 -971,000 336,000
Financing Cash Flow 1.7M -284,000 359,000 -12.2M -528,000
Cash Flow From Continuing Financing Activities 1.7M -284,000 359,000 -12.2M -528,000
Changes In Cash 3.2M -4.0M -4.0M -13.7M -2.7M
Beginning Cash Position 18.7M 22.7M 26.6M 40.3M 43.1M
End Cash Position 21.9M 18.7M 22.7M 26.6M 40.3M
Free Cash Flow 1.5M -3.7M -4.3M -1.5M -2.2M
Amortization Cash Flow 26,000 25,000 26,000 26,000 25,000
Amortization Of Intangibles 26,000 25,000 26,000 26,000 25,000
Change In Account Payable -75,000 661,000 2.0M -626,000 -580,000
Change In Accrued Expense 1.5M -618,000 -585,000 115,000 275,000
Change In Prepaid Assets 3.3M -2.3M 636,000 -14,000 1.3M
Net Income From Continuing Operations -637,000 -3.2M -1.2M -2.0M -5.7M
Net Other Financing Charges -50,000 -99,000 -12,000 -9,000 -58,000
Proceeds From Stock Option Exercised 1.8M -185,000 371,000 797,000 -470,000
Provisionand Write Offof Assets -1.7M 1.1M 79,000 199,000 4.1M
Unrealized Gain Loss On Investment Securities -- 1,000 1,000 -- --
NEWS
Loading news...
TRENDING
Loading...